Published in Cancer Weekly, November 13th, 2001
Discovered by Genzyme's antigen discovery group led by Charles A. Nicolette, PhD, the peptide ligands are superior immunogens when compared with the native gp100 epitope. The newly issued melanoma antigen patent provides synthetic peptide ligand variants of the 209 T-cell epitope of gp100 that may be useful in developing potent melanoma vaccines.
"Issuance of this patent is a key milestone for Genzyme Molecular Oncology," said Gail Maderis, president of Genzyme...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.